BACKGROUND: The benefits of treatment of hepatitis C virus with direct-acting antiviral drugs in patients with decompensated liver cirrhosis (DLC) are still unclear. AIM: To evaluate the degree of improvement in hepatic decompensation events and quality of life (QOL) in treated patients with DLC. PATIENTS AND METHODS: One hundred and fifty patients with hepatitis C virus-related DLC were included; 75 of these patients received treatment (group I) [sofosbuvir (SOF) with either daclatasvir or ledipasvir for 24 weeks without ribavirin (RBV) or for 12 weeks with RBV] and 75 patients did not receive treatment as a comparable group (group II). Patients who achieved a sustained virological response at 12 weeks were assessed in terms of decompensation events, model for end-stage liver disease score, Child-Turcotte-Pugh score, biochemical changes, and QOL (applied on Mcguill QOL questionnaire) before starting treatment and 6 months after end of treatment, and were compared with untreated patients. RESULTS: Forty-two (56%) patients received SOF/daclatasvir for 24 weeks without RBV and 19 (25.3%) patients received SOF/ledipasvir for 24 weeks without RBV. The model for end-stage liver disease score improved in treated patients (mean change -1.73), but worsened in untreated patients (mean change +11.8) before and after 6 months. Also, the Child-Turcotte-Pugh score improved significantly (P<0.001). Serum albumin, prothrombin time, bilirubin, α-fetoprotein, and alanine aminotransferase improved in treated patients (P<0.001). Health-related QOL improved in treated patients (mean change +17.65) and worsened in untreated ones (mean change -18.68; P<0.001). CONCLUSION: Treated patients with DLC showed an improvement in liver tests and health-related QOL. Longer durations of follow-up for decompensation events are needed.
BACKGROUND: The benefits of treatment of hepatitis C virus with direct-acting antiviral drugs in patients with decompensated liver cirrhosis (DLC) are still unclear. AIM: To evaluate the degree of improvement in hepatic decompensation events and quality of life (QOL) in treated patients with DLC. PATIENTS AND METHODS: One hundred and fifty patients with hepatitis C virus-related DLC were included; 75 of these patients received treatment (group I) [sofosbuvir (SOF) with either daclatasvir or ledipasvir for 24 weeks without ribavirin (RBV) or for 12 weeks with RBV] and 75 patients did not receive treatment as a comparable group (group II). Patients who achieved a sustained virological response at 12 weeks were assessed in terms of decompensation events, model for end-stage liver disease score, Child-Turcotte-Pugh score, biochemical changes, and QOL (applied on Mcguill QOL questionnaire) before starting treatment and 6 months after end of treatment, and were compared with untreated patients. RESULTS: Forty-two (56%) patients received SOF/daclatasvir for 24 weeks without RBV and 19 (25.3%) patients received SOF/ledipasvir for 24 weeks without RBV. The model for end-stage liver disease score improved in treated patients (mean change -1.73), but worsened in untreated patients (mean change +11.8) before and after 6 months. Also, the Child-Turcotte-Pugh score improved significantly (P<0.001). Serum albumin, prothrombin time, bilirubin, α-fetoprotein, and alanine aminotransferase improved in treated patients (P<0.001). Health-related QOL improved in treated patients (mean change +17.65) and worsened in untreated ones (mean change -18.68; P<0.001). CONCLUSION: Treated patients with DLC showed an improvement in liver tests and health-related QOL. Longer durations of follow-up for decompensation events are needed.
Authors: Mohsen M El-Khaiat; Ayman M El-Lehlah; Manal A Kesheita; Mohamed Abdel-Samiee; Ahmed Abozaid Ahmed Teima Journal: Ann Med Surg (Lond) Date: 2022-06-11
Authors: Mohammed Saied Bakeer; Mohamed Ibrahim Youssef; Helmy M Elshazly; Mohamed Abdel-Samiee; Abdelaleem A El-Gendy; M Abouzed; Warda Othman; Mervat Abdelkareem; Mai Abozeid; Samah Mohammed Awad; Fatma O Khalil; Hanan M Bedair; Karema A Diab; A S Seif; Marwa F Youssef; Ayman Ahmed Sakr; Eman Abdelsameea Journal: Infect Drug Resist Date: 2019-08-22 Impact factor: 4.003
Authors: Daniel Melendez-Mena; Miguel Angel Mendoza-Torres; Virginia Sedeño-Monge; Víctor Hugo García Y García; Elain Rivera-García; Laura Sánchez-Reza; María Del Carmen Baxin Domínguez; Belinda Guzmán-Flores; Ygnacio Martinez-Laguna; José Manuel Coronel Espinoza; Iván Galindo-Santiago; Juan Carlos Flores-Alonso; Verónica Vallejo-Ruiz; Paulina Cortes-Hernandez; Julio Reyes-Leyva; Francisca Sosa-Jurado; Gerardo Santos-López Journal: PeerJ Date: 2021-09-17 Impact factor: 2.984